(Q34627136)

3 August 2017

IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study (English)

1 reference

3 August 2017

1 reference

Chrystelle Brignone

1

1 reference

3 August 2017

Caroline Grygar

2

1 reference

3 August 2017

Manon Marcu

3

1 reference

3 August 2017

Gaëlle Perrin

4

1 reference

3 August 2017

Frédéric Triebel

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

24 April 2007

1 reference

3 August 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

3 August 2017

25

1 reference

3 August 2017

24

1 reference

3 August 2017

4641-4650

1 reference

A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.019

Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.019

MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine and chemokine receptor expression by human dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.019

Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.019

MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.019

Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.019

T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.019

Vaccination in humans generates broad T cell cytokine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.019

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.019

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.019

10.1016/J.VACCINE.2007.04.019

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference